The effect of adjunctive cariprazine on symptoms of anhedonia in patients with major depressive disorder
Journal of Affective Disorders · 2025-09 · 385 · 119366
DOI: 10.1016/j.jad.2025.05.026 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Affective Disorders, 2025-09. Verfasst von Roger S McIntyre und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Toronto, Toronto, ON, Canada. Electronic address: roger.mcintyre@bcdf.org. Hauptthemen laut MEDLINE: Anhedonia, Antidepressive Agents, Major Depressive Disorder, Piperazines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie Inc.
Abstract (Originalsprache)
BACKGROUND: Anhedonia is a core diagnostic symptom of major depressive disorder (MDD). Post hoc analyses evaluated cariprazine plus antidepressant treatment (ADT) in patients with MDD and moderate-to-severe anhedonia. METHODS: Data were analyzed from a positive phase 3, randomized, fixed-dose (1.5 or 3 mg/d), double-blind, placebo-controlled, parallel-group cariprazine study (NCT03738215). Post hoc outcomes (e.g., change from baseline to week 6 in MADRS total score, MADRS anhedonia subscale score, MADRS anhedonia subscale item scores including item 8 [inability to feel]) were assessed in 2 anhedonia patient subgroups (baseline MADRS anhedonia subscale score ≥ 18; baseline MADRS anhedonia item 8 score ≥ 4) using a mixed-effects model for repeated measures. RESULTS: Most patients met subgroup inclusion criteria (anhedonia subscale score ≥ 18 = 584 [77.8 %]; anhedonia item 8 score ≥ 4 = 508 [67.6 %]). LSMDs in change from baseline were statistically significant in favor of adjunctive cariprazine versus adjunctive placebo in the MADRS anhedonia subscale score ≥ 18 subgroup (MADRS total score: 1.5 mg/d = -3.4, p = .0006; 3 mg/d = -2.1, p = .0358; anhedonia subscale score: 1.5 mg/d = -2.1, p = .0010; 3 mg/d = -1.26, p = .0399) and in the anhedonia item 8 score ≥ 4 subgroup for adjunctive cariprazine 1.5 mg/d (MADRS total score: -3.2, p = .0037; anhedonia subscale score: -1.9, p = .0066). Significant differences were seen for adjunctive cariprazine versus adjunctive placebo on several anhedonia subscale single items, including anhedonia item 8 for the 1.5 mg/d dose. LIMITATION: Post hoc analysis. CONCLUSION: In patients with MDD and moderate-to-severe anhedonia, adjunctive cariprazine improved symptoms of general depression and anhedonia, suggesting a potential benefit for patients with this clinically significant symptom.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Toronto, Toronto, ON, Canada. Electronic address: roger.mcintyre@bcdf.org.
- University of South Carolina School of Medicine, Greenville, SC, USA.
- Duke-NUS Medical School, Singapore.
- AbbVie, North Chicago, IL, USA.
Förderung
- AbbVie Inc
Zitieren
APA
McIntyre, R. S., Maletic, V., Masand, P., Wilson, A. C., Yu, J., Adams, J. L., & Kerolous, M. (2025). The effect of adjunctive cariprazine on symptoms of anhedonia in patients with major depressive disorder. Journal of Affective Disorders, 385, 119366. https://doi.org/10.1016/j.jad.2025.05.026
Vancouver
McIntyre RS, Maletic V, Masand P, Wilson AC, Yu J, Adams JL, et al. The effect of adjunctive cariprazine on symptoms of anhedonia in patients with major depressive disorder. Journal of Affective Disorders. 2025;385:119366. doi:10.1016/j.jad.2025.05.026
BibTeX
@article{McIntyre2025,
author = {McIntyre, Roger S and Maletic, Vladimir and Masand, Prakash and Wilson, Andrea C and Yu, Jun and Adams, Julie L and Kerolous, Majid},
title = {The effect of adjunctive cariprazine on symptoms of anhedonia in patients with major depressive disorder},
journal = {Journal of Affective Disorders},
year = {2025},
volume = {385},
pages = {119366},
doi = {10.1016/j.jad.2025.05.026}
}
EUVIMED